Assessing the prevalence of neutralizing antibodies (NAbs) to SARS-CoV-2 during three years of the COVID-19 pandemic

IF 2.3 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemistry and Biophysics Reports Pub Date : 2024-12-17 DOI:10.1016/j.bbrep.2024.101903

Marina dos Santos Barreto , Ronaldy Santana Santos , Eloia Emanuelly Dias Silva , Deise Maria Rego Rodrigues Silva , Pedro Henrique Macedo Moura , Pamela Chaves de Jesus , Jessiane Bispo de Souza , Lucas Alves da Mota Santana , Adriana Gibara Guimarães , Lysandro Pinto Borges

{"title":"Assessing the prevalence of neutralizing antibodies (NAbs) to SARS-CoV-2 during three years of the COVID-19 pandemic","authors":"Marina dos Santos Barreto , Ronaldy Santana Santos , Eloia Emanuelly Dias Silva , Deise Maria Rego Rodrigues Silva , Pedro Henrique Macedo Moura , Pamela Chaves de Jesus , Jessiane Bispo de Souza , Lucas Alves da Mota Santana , Adriana Gibara Guimarães , Lysandro Pinto Borges","doi":"10.1016/j.bbrep.2024.101903","DOIUrl":null,"url":null,"abstract":"<div><div>The development of COVID-19 vaccines has been an important step in the fight against the pandemic. However, it is still necessary to understand the influence of factors that can alter the immune response. In general, doses need to be updated frequently, and care must be taken to control the virus that is still circulating worldwide. In this study, we evaluated the neutralizing antibodies (NAbs) against SARS-CoV-2 in northeast Brazil. The study was divided into three phases (T1, T2, and T3) and included 297 participants. The three phases occurred in three different years of the pandemic (2021, 2022 and 2023). We obtained higher mean NAbs in T2 and T3 when most of the participants had already completed their vaccination program. No significant difference in the distribution of NAbs and sex was observed (p > 0.05). It was shown that there is a difference in the expression of NAbs in the different amounts of doses, with individuals with no dose obtaining a significantly lower average than those who took the vaccine. Regarding age, the average NAbs were higher with increasing age. In this study, we assess the prevalence of NAbs in three pandemic phases, making it possible to understand the importance of vaccine updating in maintaining immunity.</div></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":"41 ","pages":"Article 101903"},"PeriodicalIF":2.3000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721800/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S240558082400267X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The development of COVID-19 vaccines has been an important step in the fight against the pandemic. However, it is still necessary to understand the influence of factors that can alter the immune response. In general, doses need to be updated frequently, and care must be taken to control the virus that is still circulating worldwide. In this study, we evaluated the neutralizing antibodies (NAbs) against SARS-CoV-2 in northeast Brazil. The study was divided into three phases (T1, T2, and T3) and included 297 participants. The three phases occurred in three different years of the pandemic (2021, 2022 and 2023). We obtained higher mean NAbs in T2 and T3 when most of the participants had already completed their vaccination program. No significant difference in the distribution of NAbs and sex was observed (p > 0.05). It was shown that there is a difference in the expression of NAbs in the different amounts of doses, with individuals with no dose obtaining a significantly lower average than those who took the vaccine. Regarding age, the average NAbs were higher with increasing age. In this study, we assess the prevalence of NAbs in three pandemic phases, making it possible to understand the importance of vaccine updating in maintaining immunity.

查看原文本刊更多论文

在COVID-19大流行的三年中评估SARS-CoV-2中和抗体（nab）的流行情况。

新冠肺炎疫苗的研发是抗击疫情的重要一步。然而，了解能够改变免疫反应的因素的影响仍然是必要的。一般来说，需要经常更新剂量，并且必须注意控制仍在世界范围内传播的病毒。在这项研究中，我们评估了巴西东北部针对SARS-CoV-2的中和抗体（nab）。研究分为三个阶段（T1、T2和T3），共有297名参与者。这三个阶段发生在大流行的三个不同年份（2021年、2022年和2023年）。当大多数参与者已经完成疫苗接种计划时，我们在T2和T3获得了更高的平均抗体。nab的分布与性别差异无统计学意义（p < 0.05）。结果表明，在不同剂量下，nab的表达存在差异，未接种疫苗的个体获得的平均水平明显低于接种疫苗的个体。在年龄方面，平均nab随年龄的增长而增加。在这项研究中，我们评估了nab在三个大流行阶段的流行情况，从而有可能了解疫苗更新对维持免疫力的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemistry and Biophysics Reports Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

4.60

自引率

0.00%

发文量

191

审稿时长

59 days

期刊介绍： Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.